Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.

Mitomycin plus BCG is as safe and effective as BCG alone, but the combination allows for a reduction in BCG doses and may help combat the BCG shortage.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.